Our results showed that SAR131675 treatment significantly reduced dyslipidemia and intrarenal lipid accumulation to the levels comparable to that of non-diabetic db/m mice and subsequently decreased TGF-β and TNF-α levels and oxidative stress. Here, TNF is linked to metabolic syndrome.